Références
(1) Development and validation of an international appraisal instrument for assessing the quality of clinical practice guidelines: the AGREE project. Qual Saf Health Care 2003; 12(1):18-23.
(2) Burgers JS, Fervers B, Haugh M, Brouwers M, Browman G, Philip T et al. International assessment of the quality of clinical practice guidelines in oncology using the Appraisal of Guidelines and Research and Evaluation Instrument. J Clin Oncol 2004; 22(10):2000-2007.
(3) Clinical practice guidelines for the treatment of unresectable non- small-cell lung cancer. Adopted on May 16, 1997 by the American Society of Clinical Oncology. J Clin Oncol 1997; 15(8):2996-3018.
(4) Pfister DG, Johnson DH, Azzoli CG, Sause W, Smith TJ, Baker S Jr et al. American Society of Clinical Oncology treatment of unresectable non-small-cell lung cancer guideline: update 2003. J Clin Oncol 2004; 22(2):330-353.
(5) BTS guidelines: guidelines on the selection of patients with lung cancer for surgery. Thorax 2001; 56(2):89-108.
(6) Levine M, Browman G, Newman T, Cowan DH. The Ontario Cancer Treatment Practice Guidelines Initiative. Oncology (Huntingt) 1996; 10(11 Suppl):19-22.
(7) The Royal College of Radiologists Clinical Oncology Information Network. Guidelines on the non-surgical management of lung cancer. Clin Oncol (R Coll Radiol ) 1999; 11(1):S1-S53.
(8) Alberts WM. Lung Cancer Guidelines. Introduction. Chest 2003; 123:1S-2S.
(9) Depierre A, Lagrange JL, Theobald S, Astoul P, Baldeyrou P, Bardet E et al. Summary report of the Standards, Options and Recommendations for the management of patients with non-small-cell lung carcinoma (2000). Br J Cancer 2003; 89 Suppl 1:S35-S49.
(10) McCrory DC, Colice GL, Lewis SZ, Alberts WM, Parker S. Overview of methodology for lung cancer evidence review and guideline development. Chest 2003; 123(1 Suppl):3S-6S.
(11) Mittal BB, Gruhn JG, Brand WN. Radiotherapy in lung cancer : a perspective from Röntgen to current concepts. In: Gruhn JG, Rosen ST, editors. Lung Cancer. The evolution of concepts. Volume II. New York: Field and Wood, 1989: 55-72.
(12) Non-small Cell Lung Cancer Collaborative Group. Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trials. BMJ 1995; 311(7010):899-909.
(13) Damstrup L, Poulsen HS. Review of the curative role of radiotherapy in the treatment of non-small cell lung cancer. Lung Cancer 1994; 11(3-4):153-178.
(14) Rowell NP, Williams CJ. Radical radiotherapy for stage I/II non-small cell lung cancer in patients not sufficiently fit for or declining surgery (medically inoperable): a systematic review. Thorax 2001; 56(8):628-638.
(15) Saunders M, Dische S, Barrett A, Harvey A, Griffiths G, Palmar M. Continuous, hyperfractionated, accelerated radiotherapy (CHART) versus conventional radiotherapy in non-small cell lung cancer: mature data from the randomised multicentre trial. CHART Steering committee [In Process Citation]. Radiother Oncol 1999; 52(2):137-148.
(16) Touboul E, Lagrange JL, Theobald S, Astoul P, Baldeyrou P, Bardet E et al. Standards, Options et Recommandations pour la prise en charge des patients atteints d'un cancer bronchique primitif de stade I ou II traités par irradiation exclusive. Cancer Radiother 2001; 5(4):452-463.
(17) Rodrigues G, Lock M, D'Souza D, Yu E, Van Dyk J. Prediction of radiation pneumonitis by dose - volume histogram parameters in lung cancer--a systematic review. Radiother Oncol 2004; 71(2):127-138.
(18) Mattson K, Holsti LR, Holsti P, Jakobsson M, Kajanti M, Liippo K et al. Inoperable non-small cell lung cancer: radiation with or without chemotherapy. Eur J Cancer Clin Oncol 1988; 24(3):477-482.
(19) Dillman RO, Seagren SL, Propert KJ, Guerra J, Eaton WL, Perry MC et al. A randomized trial of induction chemotherapy plus high-dose radiation versus radiation alone in stage III non-small-cell lung cancer. N Engl J Med 1990; 323(14):940-945.
(20) Dillman RO, Herndon J, Seagren SL, Eaton WLJ, Green MR. Improved survival in stage III non-small-cell lung cancer: seven-year follow-up of cancer and leukemia group B (CALGB) 8433 trial. J Natl Cancer Inst 1996; 88(17):1210-1215.
(21) Morton RF, Jett JR, McGinnis WL, Earle JD, Therneau TM, Krook JE et al. Thoracic radiation therapy alone compared with combined chemoradiotherapy for locally unresectable non-small cell lung cancer. A randomized, phase III trial. Ann Intern Med 1991; 115(9):681-686.
(22) Le Chevalier T, Arriagada R, Quoix E, Ruffie P, Martin M, Tarayre M et al. Radiotherapy alone versus combined chemotherapy and radiotherapy in nonresectable non-small-cell lung cancer: first analysis of a randomized trial in 353 patients. J Natl Cancer Inst 1991; 83(6):417-423.
(23) Le Chevalier T, Arriagada R, Tarayre M, Lacombe-Terrier MJ, Laplanche A, Quoix E et al. Significant effect of adjuvant chemotherapy on survival in locally advanced non-small-cell lung carcinoma. J Natl Cancer Inst 1992; 84(1):58.
(24) Gregor A, Macbeth FR, Paul J, Cram L, Hansen HH. Radical radiotherapy and chemotherapy in localized inoperable non-small- cell lung cancer: a randomized trial. J Natl Cancer Inst 1993; 85(12):997-999.
(25) Crino L, Latini P, Meacci M, Corgna E, Maranzano E, Darwish S et al. Induction chemotherapy plus high-dose radiotherapy versus radiotherapy alone in locally advanced unresectable non-small-cell lung cancer. Ann Oncol 1993; 4(10):847-851.
(26) Wolf M, Hans K, Becker H, Hassler R, von Bultzingslowen F, Goerg R et al. Radiotherapy alone versus chemotherapy with ifosfamide/vindesine followed by radiotherapy in unresectable locally advanced non-small cell lung cancer. Semin Oncol 1994; 21(3 Suppl 4):42-47.
(27) Sause WT, Scott C, Taylor S, Johnson D, Livingston R, Komaki R et al. Radiation Therapy Oncology Group (RTOG) 88-08 and Eastern Cooperative Oncology Group (ECOG) 4588: preliminary results of a phase III trial in regionally advanced, unresectable non-small-cell lung cancer. J Natl Cancer Inst 1995; 87(3):198-205.
(28) Sause W, Kolesar P, Taylor S, IV, Johnson D, Livingston R, Komaki R et al. Final results of phase III trial in regionally advanced unresectable non-small cell lung cancer: Radiation Therapy Oncology Group, Eastern Cooperative Oncology Group, and Southwest Oncology Group. Chest 2000; 117(2):358-364.
(29) Planting A, Helle P, Drings P, Dalesio O, Kirkpatrick A, McVie G et al. A randomized study of high-dose split course radiotherapy preceded by high-dose chemotherapy versus high-dose radiotherapy only in locally advanced non-small-cell lung cancer. An EORTC Lung Cancer Cooperative Group trial. Ann Oncol 1996; 7(2):139-144.
(30) Brodin O, Nou E, Mercke C, Linden CJ, Lundstrom R, Arwidi A et al. Comparison of induction chemotherapy before radiotherapy with radiotherapy only in patients with locally advanced squamous cell carcinoma of the lung. The Swedish Lung Cancer Study Group. Eur J Cancer 1996; 32A(11):1893-1900.
(31) Cullen MH, Billingham LJ, Woodroffe CM, Chetiyawardana AD, Gower NH, Joshi R et al. Mitomycin, Ifosfamide, and Cisplatin in Unresectable Non-Small-Cell Lung Cancer: Effects on Survival and Quality of Life. J Clin Oncol 1999; 17(10):3188-3194.
(32) Mattson KV, Abratt RP, Ten Velde G, Krofta K. Docetaxel as neoadjuvant therapy for radically treatable stage III non-small-cell lung cancer: a multinational randomised phase III study. Ann Oncol 2003; 14(1):116-122.
(33) Sculier JP, Berghmans T, Paesmans M, Branle F, Lemaitre F, Mascaux C et al. La place de la chimiothérapie dans le traitement des cancers bronchiques non à petites cellules non métastatiques. [The role of chemotherapy in the treatment of non-metastatic, non-small cell bronchial cancers]. Rev Med Brux 2001; 22(6):477-487.
(34) Schaake-Koning C, van den Bogaert W, Dalesio O, Festen J, Hoogenhout J, van Houtte P et al. Effects of concomitant cisplatin and radiotherapy on inoperable non- small-cell lung cancer. N Engl J Med 1992; 326(8):524-530.
(35) Trovo MG, Minatel E, Franchin G, Boccieri MG, Nascimben O, Bolzicco G et al. Radiotherapy versus radiotherapy enhanced by cisplatin in stage III non- small cell lung cancer. Int J Radiat Oncol Biol Phys 1992; 24(1):11-15.
(36) Blanke C, Ansari R, Mantravadi R, Gonin R, Tokars R, Fisher W et al. Phase III trial of thoracic irradiation with or without cisplatin for locally advanced unresectable non-small-cell lung cancer: a Hoosier Oncology Group protocol. J Clin Oncol 1995; 13(6):1425-1429.
(37) Jeremic B, Shibamoto Y, Acimovic L, Djuric L. Randomized trial of hyperfractionated radiation therapy with or without concurrent chemotherapy for stage III non-small-cell lung cancer. J Clin Oncol 1995; 13(2):452-458.
(38) Jeremic B, Shibamoto Y, Acimovic L, Milisavljevic S. Hyperfractionated radiation therapy with or without concurrent low-dose daily carboplatin/etoposide for stage III non-small-cell lung cancer: a randomized study. J Clin Oncol 1996; 14(4):1065-1070.
(39) Bonner JA, McGinnis WL, Stella PJ, Marschke RFJ, Sloan JA, Shaw EG et al. The possible advantage of hyperfractionated thoracic radiotherapy in the treatment of locally advanced nonsmall cell lung carcinoma: results of a North Central Cancer Treatment Group Phase III Study. Cancer 1998; 82(6):1037-1048.
(40) Clamon G, Herndon J, Cooper R, Chang AY, Rosenman J, Green MR. Radiosensitization with carboplatin for patients with unresectable stage III non-small-cell lung cancer: a phase III trial of the Cancer and Leukemia Group B and the Eastern Cooperative Oncology Group. J Clin Oncol 1999; 17(1):4-11.
(41) Groen HJ, Van Der Leest AH, Fokkema E, Timmer PR, Nossent GD, Smit WJ et al. Continuously infused carboplatin used as radiosensitizer in locally unresectable non-small-cell lung cancer: a multicenter phase III study. Ann Oncol 2004; 15(3):427-432.
(42) Cakir S, Egehan I. A randomised clinical trial of radiotherapy plus cisplatin versus radiotherapy alone in stage III non-small cell lung cancer. Lung Cancer 2004; 43(309):318.
(43) Ball D, Bishop J, Smith J, O'Brien P, Davis S, Ryan G et al. A randomised phase III study of accelerated or standard fraction radiotherapy with or without concurrent carboplatin in inoperable non- small cell lung cancer: final report of an Australian multi-centre trial. Radiother Oncol 1999; 52(2):129-136.
(44) Rakovitch E, Tsao M, Ung Y, Pignol JP, Cheung P, Chow E. Comparison of the efficacy and acute toxicity of weekly versus daily chemoradiotherapy for non-small-cell lung cancer: a meta-analysis. Int J Radiat Oncol Biol Phys 2004; 58(1):196-203.
(45) Johnson DH, Einhorn LH, Bartolucci A, Birch R, Omura G, Perez CA et al. Thoracic radiotherapy does not prolong survival in patients with locally advanced, unresectable non-small cell lung cancer. Ann Intern Med 1990; 113(1):33-38.
(46) Kubota K, Furuse K, Kawahara M, Kodama N, Yamamoto M, Ogawara M et al. Role of radiotherapy in combined modality treatment of locally advanced non-small-cell lung cancer. J Clin Oncol 1994; 12(8):1547-1552.
(47) Sculier JP, Paesmans M, Lafitte JJ, Baumohl J, Thiriaux J, van Cutsem O et al. A randomised phase III trial comparing consolidation treatment with further chemotherapy to chest irradiation in patients with initially unresectable locoregional non-small-cell lung cancer responding to induction chemotherapy. European Lung Cancer Working Party. Ann Oncol 1999; 10(3):295-303.
(48) Kaasa S, Thorud E, Host H, Lien HH, Lund E, Sjolie I. A randomized study evaluating radiotherapy versus chemotherapy in patients with inoperable non-small cell lung cancer. Radiother Oncol 1988; 11(1):7-13.
(49) Johnstone DW, Byhardt RW, Ettinger D, Scott CB. Phase III study comparing chemotherapy and radiotherapy with preoperative chemotherapy and surgical resection in patients with non-small-cell lung cancer with spread to mediastinal lymph nodes (N2); final report of RTOG 89-01. Radiation Therapy Oncology Group. Int J Radiat Oncol Biol Phys 2002; 54(2):365-369.
(50) Komaki R, Seiferheld W, Ettinger D, Lee JS, Movsas B, Sause W. Randomized phase II chemotherapy and radiotherapy trial for patients with locally advanced inoperable non-small-cell lung cancer: long-term follow-up of RTOG 92-04. Int J Radiat Oncol Biol Phys 2002; 53(3):548-557.
(51) Belani CP, Choy H, Bonomi P, Scott C, Travis P, Haluschak J et al. Combined chemoradiotherapy regimens of paclitaxel and carboplatin for locally advanced non-small-cell lung cancer: a randomized phase II locally advanced multi-modality protocol. J Clin Oncol 2005; 23(25):5883-5891.
(52) Furuse K, Fukuoka M, Kawahara M, Nishikawa H, Takada Y, Kudoh S et al. Phase III study of concurrent versus sequential thoracic radiotherapy in combination with mitomycin, vindesine, and cisplatin in unresectable stage III non-small-cell lung cancer. J Clin Oncol 1999; 17(9):2692.
(53) Zatloukal P, Petruzelka L, Zemanova M, Havel L, Janku F, Judas L et al. Concurrent versus sequential chemoradiotherapy with cisplatin and vinorelbine in locally advanced non-small cell lung cancer: a randomized study. Lung Cancer 2004; 46(1):87-98.
(54) Fournel P, Robinet G, Thomas P, Souquet PJ, Lena H, Vergnenegre A et al. Randomized phase III trial of sequential chemoradiotherapy compared with concurrent chemoradiotherapy in locally advanced non-small-cell lung cancer: Groupe Lyon-Saint-Etienne d'Oncologie Thoracique-Groupe Francais de Pneumo-Cancerologie NPC 95-01 Study. J Clin Oncol 2005; 23(25):5910-5917.
(55) Vokes EE, Herndon JE, Crawford J, Leopold KA, Perry MC, Miller AA et al. Randomized phase II study of cisplatin with gemcitabine or paclitaxel or vinorelbine as induction chemotherapy followed by concomitant chemoradiotherapy for stage IIIB non-small-cell lung cancer: cancer and leukemia group B study 9431. J Clin Oncol 2002; 20(20):4191-4198.
(56) Sculier JP, Lafitte JJ, Berghmans T, van Houtte P, Lecomte J, Thiriaux J et al. A phase III randomised study comparing two different dose-intensity regimens as induction chemotherapy followed by thoracic irradiation in patients with advanced locoregional non-small-cell lung cancer. Ann Oncol 2004; 15(3):399-409.
(57) Belani CP, Wang W, Johnson DH, Wagner H, Schiller J, Veeder M et al. Phase III study of the Eastern Cooperative Oncology Group (ECOG 2597): induction chemotherapy followed by either standard thoracic radiotherapy or hyperfractionated accelerated radiotherapy for patients with unresectable stage IIIA and B non-small-cell lung cancer. J Clin Oncol 2005; 23(16):3760-3767.
(58) Senan S, De Ruysscher D, Giraud P, Mirimanoff R, Budach V. Literature-based recommendations for treatment planning and execution in high-dose radiotherapy for lung cancer. Radiother Oncol 2004; 71(2):139-146.
(59) Armstrong JG. Target volume definition for three-dimensional conformal radiation therapy of lung cancer. Br J Radiol 1998; 71(846):587-594.
(60) Bradley J, Thorstad WL, Mutic S, Miller TR, Dehdashti F, Siegel BA et al. Impact of FDG-PET on radiation therapy volume delineation in non-small-cell lung cancer. Int J Radiat Oncol Biol Phys 2004; 59(1):78-86.
(61) Marino P, Preatoni A, Cantoni A. Randomized trials of radiotherapy alone versus combined chemotherapy and radiotherapy in stages IIIa and IIIb nonsmall cell lung cancer. A meta-analysis. Cancer 1995; 76(4):593-601.
(62) Pritchard RS, Anthony SP. Chemotherapy plus radiotherapy compared with radiotherapy alone in the treatment of locally advanced, unresectable, non-small-cell lung cancer. A meta-analysis [published erratum appears in Ann Intern Med 1997 Apr 15;126(8):670]. Ann Intern Med 1996; 125(9):723-729.